Aligos Therapeutics (NASDAQ:ALGS) Shares Down 3.6% - Here's What Happened

Key Points

• Aligos Therapeutics shares fell by 3.6% to $9.49, with trading volume down significantly from the average.
• Research analysts issued mixed ratings, with Weiss Ratings maintaining a "sell (d-)" while HC Wainwright maintains a "buy" rating with a price target of $50.00.
• Institutional investors hold 60.43% of Aligos Therapeutics' stock, indicating significant interest from large funds.

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) were down 3.6% on Thursday . The company traded as low as $9.25 and last traded at $9.49. Approximately 76,223 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 98,679 shares. The stock had previously closed at $9.84.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ALGS shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Aligos Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Aligos Therapeutics in a research note on Friday, September 12th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Aligos Therapeutics currently has an average rating of "Hold" and an average target price of $50.00.

Aligos Therapeutics Trading Down 3.6%

The firm has a market cap of $58.36 million, a price-to-earnings ratio of -0.48 and a beta of 2.77. The company has a 50 day moving average of $10.07 and a 200 day moving average of $7.87.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.82. The business had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%. Equities analysts forecast that Aligos Therapeutics, Inc. will post -10.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of large investors have recently added to or reduced their stakes in ALGS. Alyeska Investment Group L.P. bought a new position in Aligos Therapeutics during the 1st quarter worth about $3,399,000. Woodline Partners LP bought a new position in Aligos Therapeutics during the 1st quarter worth about $2,602,000. Heights Capital Management Inc. bought a new position in Aligos Therapeutics during the 1st quarter worth about $1,992,000. Sio Capital Management LLC increased its holdings in Aligos Therapeutics by 85.9% during the 2nd quarter. Sio Capital Management LLC now owns 335,937 shares of the company's stock worth $2,422,000 after purchasing an additional 155,217 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its holdings in Aligos Therapeutics by 43.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company's stock worth $3,836,000 after purchasing an additional 140,000 shares in the last quarter. Institutional investors own 60.43% of the company's stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.